Acute Kidney Injury: Pre-renal, Intrinsic, and Post-renal Classifications

Acute Kidney Injury (AKI) is defined as an abrupt decrease in kidney function occurring over hours to days, characterized by accumulation of nitrogenous waste products and dysregulation of extracellular volume and electrolytes [5]. The KDIGO guidelines define AKI by any of the following criteria:

• Serum creatinine increase ≥0.3 mg/dL (26.5 μmol/L) within 48 hours • Serum creatinine increase ≥1.5 times baseline within 7 days • Urine output <0.5 mL/kg/h for 6 hours

[HIGH_YIELD] AKI is classified into three main categories based on the anatomical location of the primary pathology:

[KEY_CONCEPT] Acute Kidney Diseases and Disorders (AKD) represents the spectrum between normal kidney function and established AKI or CKD, encompassing conditions that may not meet strict AKI criteria but represent acute changes in kidney function [5].

AKI Staging (KDIGO):

• Stage 1: SCr 1.5-1.9× baseline or ≥0.3 mg/dL increase; UO <0.5 mL/kg/h × 6-12h
• Stage 2: SCr 2.0-2.9× baseline; UO <0.5 mL/kg/h × ≥12h
• Stage 3: SCr ≥3.0× baseline or ≥4.0 mg/dL or initiation of RRT; UO <0.3 mL/kg/h × ≥24h or anuria × ≥12h

[CLINICAL_PEARL] Early recognition and classification of AKI type is crucial for appropriate management, as pre-renal AKI is often reversible with prompt intervention, while intrinsic AKI may lead to permanent kidney damage.

Pre-renal AKI results from decreased renal perfusion with structurally normal kidneys. The kidney responds appropriately by conserving sodium and water, leading to concentrated urine with low sodium content.

Pathophysiology:

• Reduced effective circulating volume
• Activation of renin-angiotensin-aldosterone system (RAAS)
• Increased antidiuretic hormone (ADH) release
• Preserved tubular function initially

Common Causes:

Volume Depletion: • Hemorrhage, burns, severe dehydration • Gastrointestinal losses (vomiting, diarrhea) • Diuretic overuse, osmotic diuresis

Decreased Cardiac Output: • Heart failure, cardiogenic shock • Massive pulmonary embolism • Pericardial tamponade

Systemic Vasodilation: • Sepsis, anaphylaxis • Medications (ACE inhibitors, ARBs, vasodilators) • Hepatorenal syndrome

[HIGH_YIELD] Laboratory Findings in Pre-renal AKI:

[KEY_CONCEPT] Fractional Excretion of Sodium (FENa) = (Urine Na × Plasma Cr) / (Plasma Na × Urine Cr) × 100%

[CLINICAL_PEARL] FEUrea may be more accurate than FENa in patients receiving diuretics, as diuretics affect sodium handling but not urea reabsorption.

Intrinsic AKI involves direct damage to kidney structures, including glomeruli, tubules, interstitium, or vasculature. This represents true kidney injury with impaired concentrating ability.

Classification by Anatomical Site:

1. Acute Tubular Necrosis (ATN) - 85% of intrinsic AKI

Ischemic ATN: • Prolonged hypotension, shock • Major surgery, cardiac arrest • Severe dehydration

Nephrotoxic ATN: • Medications: Aminoglycosides, vancomycin, amphotericin B, cisplatin, contrast agents • Endogenous toxins: Myoglobin (rhabdomyolysis), hemoglobin (hemolysis) • Environmental: Heavy metals, organic solvents

2. Acute Glomerulonephritis • Anti-GBM disease, ANCA vasculitis • Post-infectious glomerulonephritis • Systemic lupus erythematosus

3. Acute Interstitial Nephritis (AIN) • Drug-induced: NSAIDs, antibiotics, PPIs, diuretics • Infectious: Bacteria, viruses, fungi • Systemic diseases: Sarcoidosis, Sjögren's syndrome

[HIGH_YIELD] ATN Phases:

1. Initiation (hours to days): Initial injury
2. Extension (days to weeks): Continued injury and inflammation
3. Maintenance (1-3 weeks): Established AKI
4. Recovery (days to months): Tubular repair and regeneration

Laboratory/Urinalysis Findings:

[CLINICAL_PEARL] The presence of muddy brown granular casts is pathognomonic for ATN, while RBC casts indicate glomerular disease.

Post-renal AKI results from obstruction of urine flow anywhere from the renal pelvis to the urethral meatus. Obstruction must be bilateral (or unilateral in a patient with a single functioning kidney) to cause AKI.

Common Causes by Location:

Upper Urinary Tract: • Nephrolithiasis, blood clots • Malignancy (intrinsic or extrinsic compression) • Retroperitoneal fibrosis • Papillary necrosis

Lower Urinary Tract: • Benign prostatic hyperplasia (most common) • Prostate cancer, bladder cancer • Neurogenic bladder • Urethral strictures

[KEY_CONCEPT] Diagnostic Algorithm for AKI:

AKI Suspected (↑SCr, ↓UO) | ▼ History & Physical Exam • Volume status assessment • Medication review • Urinary symptoms | ▼ Urinalysis & Microscopy • Proteinuria, hematuria • Casts, crystals, cells | ▼ Renal Ultrasound • Hydronephrosis? • Kidney size/echogenicity | ┌───▼───┐ │ │ Hydronephrosis No Hydronephrosis │ │ ▼ ▼ Post-renal AKI Pre-renal vs Intrinsic │ │ ▼ ▼ Urology consult Calculate FENa/FEUrea • Relief of • Volume challenge if obstruction pre-renal suspected

[HIGH_YIELD] Diagnostic Tests:

Essential Studies: • Complete metabolic panel (SCr, BUN, electrolytes) • Urinalysis with microscopy • Urine electrolytes (FENa, FEUrea) • Renal ultrasound

Additional Studies (when indicated): • Urine protein/creatinine ratio • Complement levels (C3, C4) • Autoantibodies (ANA, ANCA, anti-GBM) • Serum/urine protein electrophoresis • Kidney biopsy (if glomerulonephritis suspected)

[CLINICAL_PEARL] Renal ultrasound should be performed within 24 hours in all AKI patients to rule out obstruction, especially if no clear pre-renal cause is identified.

AKI management focuses on treating the underlying cause, optimizing hemodynamics, avoiding nephrotoxins, and preventing complications.

General Management Principles:

1. Address Underlying Cause • Pre-renal: Volume resuscitation, optimize cardiac output • Intrinsic: Discontinue nephrotoxins, treat underlying disease • Post-renal: Urgent urological intervention

2. Supportive Care • Maintain euvolemia • Optimize blood pressure (MAP >65 mmHg) • Avoid nephrotoxic medications • Adjust medication dosing for kidney function

[HIGH_YIELD] Fluid Management Algorithm:

Volume Status Assessment | ┌───▼───┐ │ │ Hypovolemic Euvolemic/Hypervolemic │ │ ▼ ▼ Fluid Challenge Fluid Restriction • 500-1000mL NS • <1.5L/day • Reassess in 1-2h • Daily weights │ • Monitor I/Os ▼ │ Improvement? ▼ │ Diuretics if volume ┌───▼───┐ overloaded │ │ • Furosemide Yes No • Monitor electrolytes │ │ ▼ ▼ Continue Consider management RRT

3. Pharmacological Interventions

Diuretics: • Loop diuretics (furosemide 20-80mg IV) for volume overload • No proven benefit for kidney recovery • May facilitate fluid management

Avoid/Use with Caution: • NSAIDs, ACE inhibitors/ARBs (if hemodynamically unstable) • Aminoglycosides, vancomycin, contrast agents • Metformin (risk of lactic acidosis)

[KEY_CONCEPT] Indications for Renal Replacement Therapy (RRT): • Acidosis (pH <7.1) • Electrolyte abnormalities (hyperkalemia >6.5 mEq/L) • Intoxications (methanol, ethylene glycol, lithium, salicylates) • Overload (pulmonary edema refractory to diuretics) • Uremia (pericarditis, encephalopathy, bleeding)

4. Monitoring Parameters • Daily weights, intake/output • Serum creatinine, BUN, electrolytes (daily) • Urine output (hourly if critically ill) • Signs of volume overload or uremia

[CLINICAL_PEARL] Early nephrology consultation is recommended for Stage 2-3 AKI, unclear etiology, or need for RRT consideration.

AKI complications can be immediate or long-term, significantly impacting patient morbidity and mortality.

Acute Complications:

Fluid & Electrolyte Imbalances: • Hyperkalemia: Most dangerous acute complication • Metabolic acidosis: Gap or non-gap • Hyperphosphatemia, hyponatremia • Volume overload: Pulmonary edema, hypertension

Uremic Complications: • Uremic encephalopathy: Confusion, seizures, coma • Uremic pericarditis: Chest pain, friction rub • Uremic bleeding: Platelet dysfunction

[HIGH_YIELD] Hyperkalemia Management in AKI:

Long-term Consequences:

Chronic Kidney Disease Development: • 25-50% of AKI survivors develop CKD [1] • Risk factors: Severity of AKI, underlying CKD, diabetes • Requires long-term nephrology follow-up

Cardiovascular Risk: • Increased risk of heart failure, MI, stroke [1] • Accelerated atherosclerosis • Hypertension development

Prognosis Factors:

Good Prognosis: • Pre-renal AKI with prompt treatment • Young age, no comorbidities • Single episode, complete recovery

Poor Prognosis: • Advanced age, multiple comorbidities • Severe AKI (Stage 3) requiring RRT • Delayed recognition/treatment • Underlying CKD

[KEY_CONCEPT] Recovery Patterns:

• Complete recovery: SCr returns to baseline (40-60%)
• Partial recovery: Improved but elevated SCr (20-30%)
• No recovery: Persistent elevation, may need chronic RRT (10-20%)

Prevention Strategies: • Avoid nephrotoxins when possible • Maintain adequate hydration during procedures • Monitor high-risk patients closely • Early recognition and intervention

[CLINICAL_PEARL] Even complete recovery from AKI carries long-term risks; patients require ongoing monitoring of kidney function and cardiovascular health.